Lv51
1190 积分 2023-11-16 加入
Asundexian for Secondary Stroke Prevention
4小时前
已完结
Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial
5小时前
已完结
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial
18天前
已完结
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
19天前
已完结
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
19天前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
20天前
已完结
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis
1个月前
已完结
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection
1个月前
已完结
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
1个月前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
1个月前
已关闭
皖公网安备34019202002308
